Validation Data Gallery
Tested Applications
| Positive WB detected in | mouse liver tissue, mouse spleen tissue, human adrenal gland tissue | 
| Positive IP detected in | mouse spleen tissue | 
| Positive IHC detected in | human breast cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 | 
Recommended dilution
| Application | Dilution | 
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 | 
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate | 
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 | 
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below | 
| WB | See 9 publications below | 
| IHC | See 5 publications below | 
| CoIP | See 1 publications below | 
Product Information
14905-1-AP targets PSMC2 in WB, IHC, IP, CoIP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat | 
| Cited Reactivity | human, mouse, rat | 
| Host / Isotype | Rabbit / IgG | 
| Class | Polyclonal | 
| Type | Antibody | 
| Immunogen | CatNo: Ag6700 Product name: Recombinant human PSMC2 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 84-433 aa of BC002589 Sequence: KQTLQSEQPLQVARCTKIINADSEDPKYIINVKQFAKFVVDLSDQVAPTDIEEGMRVGVDRNKYQIHIPLPPKIDPTVTMMQVEEKPDVTYSDVGGCKEQIEKLREVVETPLLHPERFVNLGIEPPKGVLLFGPPGTGKTLCARAVANRTDACFIRVIGSELVQKYVGEGARMVRELFEMARTKKACLIFFDEIDAIGGARFDDGAGGDNEVQRTMLELINQLDGFDPRGNIKVLMATNRPDTLDPALMRPGRLDRKIEFSLPDLEGRTHIFKIHARSMSVERDIRFELLARLCPNSTGAEIRSVCTEAGMFAIRARRKIATEKDFLEAVNKVIKSYAKFSATPRYMTYN相同性解析による交差性が予測される生物種 | 
| Full Name | proteasome (prosome, macropain) 26S subunit, ATPase, 2 | 
| Calculated molecular weight | 49 kDa | 
| Observed molecular weight | 49 kDa | 
| GenBank accession number | BC002589 | 
| Gene Symbol | PSMC2 | 
| Gene ID (NCBI) | 5701 | 
| RRID | AB_2172484 | 
| Conjugate | Unconjugated | 
| Form | |
| Form | Liquid | 
| Purification Method | Antigen affinity purification | 
| UNIPROT ID | P35998 | 
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 | 
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. | 
Background Information
PSMC2 is also named as MSS1 and belongs to the AAA ATPase family. PSMC2 is 1 of 6 putative ATPases contained within the regulatory complex. PSMC2 is first identified as a possible cellular factor that cooperates with the human immunodeficiency virus-1 (HIV-1) protein Tat, a potent activator of virus gene expression. The PSMC2 gene product works in association with the small subunit of mitoribosomes and seems to play some part in mitochondrial translation(PMID:8392589).
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for PSMC2 antibody 14905-1-AP | Download protocol | 
| IP protocol for PSMC2 antibody 14905-1-AP | Download protocol | 
| WB protocol for PSMC2 antibody 14905-1-AP | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 
Publications
| Species | Application | Title | 
|---|---|---|
| Gastroenterology Proteomic characterization identifies clinically relevant subgroups of gastrointestinal stromal tumors | ||
| Front Immunol PDLIM7 Synergizes With PDLIM2 and p62/Sqstm1 to Inhibit Inflammatory Signaling by Promoting Degradation of the p65 Subunit of NF-κB. | ||
| Cardiovasc Drugs Ther Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway. | ||
| Calcif Tissue Int Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo.
 | ||
| Oncol Lett PSMC2, ORC5 and KRTDAP are specific biomarkers for HPV-negative head and neck squamous cell carcinoma. | ||
| Pharmgenomics Pers Med PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer | 









